KOSDAQBiotech & Pharma245620

Eone Diagnomics Genome Center

₩741 0.00%2026-10-02 close

Market Cap

₩167.1B

Turnover

₩0

Volume

0 shares

Shares out.

230M

PER

2.7×

PBR

6.0×

EPS

₩272

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Rehabilitation Restructuring Done, Core Business Recovery Still Pending

EDGC has completed a court-approved rehabilitation restructuring of its capital structure, but its core genomic analysis and diagnostics business is still posting operating losses.

1
Under a court-approved rehabilitation plan from March 2026, debt-to-equity conversion, a 6-to-1 reverse stock split, and a third-party capital increase were carried out in sequence.
2
Healthcare group Iroom Holdings became the largest shareholder and is exploring integration with precision medicine and health-supplement businesses.
3
The large net profits in the fourth quarter of 2025 and the first quarter of 2026 were mostly one-off effects tied to debt restructuring, while operating profit has stayed negative for five straight quarters.
4
An injunction against the November 2025 delisting decision has kept the stock trading, but the outcome of the underlying lawsuit could still determine whether the listing is maintained.
5
Capital impairment has persisted through 2024 and 2025, so the swing to net profit does not by itself indicate that the balance sheet has normalized.

Business structure

EDGC (Eone Diagnomics Genome Center) is a Korea-US joint-venture genomic analysis company founded in 2013 in Incheon Songdo by Iwon Medical Foundation and US-based Diagnomics, and it listed on KOSDAQ in 2018 under the technology special-listing track.

Its core services are the direct-to-consumer genetic test YouWho, the non-invasive prenatal genetic test NICE, and blood-based liquid biopsy diagnostics under the EDGC-SCAN and OncoCatch brands.

The company also owns health-supplement manufacturing and packaging facilities, giving it production capacity that could be linked to group-level supplement businesses.

However, three consecutive years of operating losses from 2021 through 2023 led to a disclaimer of opinion from its external auditor in April 2024, triggering formal delisting grounds, and the company filed for court rehabilitation with the Seoul Rehabilitation Court the following May.

In November 2025 the KOSDAQ Market Committee decided to delist the company, but EDGC filed an injunction with the Seoul Southern District Court to suspend the delisting decision, and both the liquidation trading and delisting procedures remain on hold.

During this process, health-supplement and healthcare company Iroom Holdings (formerly Iroom Group, led by Chairman Hwang Seong-ju) decided to acquire the rehabilitation company EDGC, in what is viewed as its first major deal in a healthcare-centered business pivot.

Iroom Holdings is pursuing a strategy of combining subsidiary Hugen Bio's liquid-biopsy-based molecular diagnostics technology with EDGC's genomic data and diagnostic capabilities to expand into precision medicine and data-driven healthcare.

The rehabilitation plan was approved by the Suwon Rehabilitation Court on March 20, 2026, and debt-to-equity conversion of rehabilitation claims, a 6-to-1 reverse stock split, and a third-party capital increase were subsequently carried out in sequence.

Following this restructuring, the shareholder structure changed significantly, and the company is seeking business normalization while market actions related to listing eligibility and investor-caution designation remain in flux.

Earnings trend

Quarterly revenue · Operating profit

₩700M25Q2₩1.8B-₩400M25Q3₩1.7B-₩400M25Q4₩1.6B-₩1.3B26Q1₩1.2B-₩700M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩94.2B-₩9.5B2022₩88.5B-₩9.4B2023₩30.9B-₩12.6B2024₩7.9B-₩1.6B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	₩700M	—
2025Q3	₩1.8B	-₩400M	−23.2%
2025Q4	₩1.7B	-₩400M	−21.2%
2026Q1	₩1.6B	-₩1.3B	−81.4%
2026Q2	₩1.2B	-₩700M	−58.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩94.2B	-₩9.5B	-₩29.9B	−10.1%	−93.5%	484.8%
2023	₩88.5B	-₩9.4B	-₩33B	−10.6%	−86.4%	343.7%
2024	₩30.9B	-₩12.6B	-₩95.2B	−40.8%	—	−294.5%
2025	₩7.9B	-₩1.6B	₩28.2B	−20.2%	—	−295.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated revenue fell sharply from about KRW 94.2 billion in 2022 and KRW 88.5 billion in 2023 to KRW 30.9 billion in 2024, and further down to KRW 7.9 billion in 2025, shrinking to roughly one-eighth of its level four years earlier.

The company attributed this revenue decline mainly to a reduction in the number of subsidiaries during the rehabilitation process and to the disposal of subsidiaries following the exercise of stock pledges.

Operating losses widened from about KRW 9.5 billion in 2022 to KRW 9.4 billion in 2023 and KRW 12.6 billion in 2024, before narrowing to KRW 1.6 billion in 2025, likely reflecting cost reductions that accompanied the shrinking revenue base.

Net income attributable to owners posted large losses for three straight years — about KRW 29.9 billion in 2022, KRW 33.0 billion in 2023, and KRW 95.2 billion in 2024 — before swinging to a profit of about KRW 28.2 billion in 2025.

On a quarterly basis, net income to owners swung sharply: about negative KRW 0.4 billion in the third quarter of 2025, positive KRW 20.2 billion in the fourth quarter, positive KRW 24.7 billion in the first quarter of 2026, and negative KRW 0.7 billion in the second quarter, while operating losses of roughly KRW 0.4 billion, KRW 0.4 billion, KRW 1.3 billion, and KRW 0.7 billion persisted in each of those same quarters — indicating that the net income spikes stemmed not from the core business but from one-off gains tied to debt restructuring and debt-to-equity conversion under the rehabilitation plan.

As a result, net income to owners summed over the most recent four quarters (third quarter of 2025 through second quarter of 2026) came to about KRW 43.7 billion, but most of this should be understood as one-off balance-sheet-repair effects concentrated in the fourth quarter of 2025 and first quarter of 2026.

Total equity attributable to owners moved from about KRW 38.2 billion in 2023 to negative KRW 45.2 billion in 2024 and negative KRW 22.5 billion in 2025, meaning capital impairment has persisted and the swing to net profit does not by itself signal balance-sheet normalization.

On a more constructive note, operating cash flow turned positive for two consecutive years, at about KRW 6.7 billion in 2024 and KRW 3.5 billion in 2025, after being negative at about KRW 10.9 billion in 2022 and KRW 14.0 billion in 2023, which can be read as a somewhat positive signal for cash generation.

Industry analysis

Korea's genomic analysis and diagnostics industry has seen slowing growth since the end of pandemic-era demand, exposing many small and mid-sized genomics and diagnostics companies to weak earnings and financial pressure.

During this period, several KOSDAQ-listed bio and diagnostics companies faced listing-maintenance issues such as auditor disclaimers of opinion and listing-eligibility reviews, with companies including Pharmabcine, Celleverine, Celestrahigh, PCL, and Intromedic all coming under delisting review around the same period.

In the liquid biopsy field, global players such as US-based GRAIL and Illumina have taken an early technology lead, while domestic competitors alongside EDGC include Labgenomics, Theragen Bio, Macrogen, DNA Link, and Clinomics, all holding comparable genomic analysis technologies.

Domestic genomics companies have previously formed competing consortiums for large government-led projects such as the national bio big-data initiative known as K-DNA, but EDGC's deteriorating financial condition in recent years made it difficult to actively participate in such large-scale projects.

The Korea Exchange has been tightening listing-maintenance requirements, including phased increases in the minimum market-cap threshold for KOSDAQ listing, suggesting continued consolidation in the genomics and diagnostics sector.

On the other hand, demand for precision medicine and personalized health management continues to expand structurally, and attempts to combine health-supplement and healthcare platforms with genomic data continue both in Korea and abroad.

Against this backdrop, EDGC is attempting to broaden its business into precision medicine and preventive-care services after joining a healthcare group, while simultaneously facing the twin challenges of balance-sheet normalization and revenue recovery.

Outlook

The company's top priority is the outcome of litigation related to listing eligibility, since whether the listing is maintained hinges on this result, and follow-up market actions such as lifting the administrative-issue and investor-caution designations can only proceed once it is finalized.

The capital-structure overhaul under the March 2026 rehabilitation plan approval — debt-to-equity conversion, reverse stock split, and capital increase — has been completed, and the related new shares were listed on June 12, 2026, which is expected to contribute partially to easing capital impairment.

Iroom Holdings, now the largest shareholder, has signaled plans to combine subsidiary Hugen Bio's liquid-biopsy-based molecular diagnostics technology with EDGC's genomic data and diagnostic infrastructure to expand into precision medicine and preventive-care services.

Market observers point to potential mid- to long-term synergies such as linking EDGC's health-supplement production facilities with Iroom Holdings' existing supplement business, or collaborating on testing and diagnostics with an affiliated hospital.

However, these synergies have not yet been confirmed through specific contracts or revenue contribution, and actual commercialization is likely to take time.

Because revenue from the core genomic analysis and diagnostics business has fallen sharply through the rehabilitation process, the pace of revenue recovery and any improvement in operating profit in coming quarters will be the key indicators of normalization.

Given that the company has previously explored various new ventures such as dementia-drug research and cultured-meat projects, how new-business priorities are reordered after joining the Iroom Holdings group is also worth watching.

Valuation

PER

2.7×

PBR

6.0×

ROE

296.5%

EPS

₩272

BPS

₩124

Dividend per share

₩0

With net income summed over the most recent four quarters having risen sharply, the price-to-earnings multiple now sits in a lower range than the trading multiples seen during the company's period of large losses.

However, this earnings improvement stems mostly from one-off balance-sheet-repair effects tied to debt restructuring and debt-to-equity conversion under the rehabilitation plan rather than from a turnaround in core operating profit, and the multiple should be interpreted with that in mind.

Looking at the relationship between share price and net assets, the company is in a transitional phase of emerging from capital impairment, making it difficult to directly compare its price-to-book premium level with typical industry averages.

No dividend is currently being paid, so valuation comparisons based on dividend yield have limited relevance. As a result, this stock's valuation metrics sit in a range that needs to be interpreted in light of the special circumstances of a rehabilitation and restructuring phase, unlike a standard profitable company.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Rehabilitation Process Completed and Capital Structure Overhauled

Following the court's rehabilitation plan approval in March 2026, debt-to-equity conversion, a reverse stock split, and a capital increase were carried out in sequence as structural measures to ease capital impairment. The related new shares completed their revised listing in June of the same year.

Net income summed over the most recent four quarters also turned positive, though it should be noted that this was driven largely by one-off factors.

Potential Business Synergies From Joining a Healthcare Group

The acquisition by Iroom Holdings has opened the possibility of integration with precision medicine, health-supplement, and hospital networks. If subsidiary Hugen Bio's liquid-biopsy technology is combined with EDGC's genomic data capabilities, there is room for new service line expansion. However, a concrete commercialization timeline has not yet been disclosed.

Improved Operating Cash Flow

Operating cash flow was positive for two consecutive years in 2024 and 2025, an improvement in cash generation compared with the earlier period of negative cash flow. This appears to have been accompanied by cost-structure efficiencies made in response to the shrinking revenue base. This could contribute to easing liquidity pressure.

Bear factors

Core Business Operating Losses Persist

Operating losses have continued every quarter from the third quarter of 2025 through the second quarter of 2026, so an improvement in core-business profitability has not yet been confirmed despite the swing to net profit. Revenue scale also remains far below past levels. Without a revenue recovery, it is difficult to speak of a structural turnaround.

Litigation Risk Tied to Listing Eligibility

An injunction filed by the company against the KOSDAQ Market Committee's November 2025 delisting decision has been granted, suspending liquidation trading, but there remains a possibility that delisting procedures could resume depending on the outcome of the underlying lawsuit. Until this uncertainty is resolved, market actions such as the investor-caution designation also remain fluid.

Ongoing Capital Impairment and Share Dilution

Total equity remained negative in both 2024 and 2025, indicating ongoing capital impairment. The large-scale debt-to-equity conversion and capital increase under the rehabilitation plan sharply increased the share count, diluting existing shareholders. Further dilution cannot be ruled out if additional capital raising is needed in the future.

Risk factors

Delisting and Litigation Risk

Trading has continued thanks to an injunction against the delisting decision, but delisting procedures could resume depending on the outcome of the underlying lawsuit.

The listing-eligibility substantive review itself is set to proceed only after the formal delisting grounds are resolved, meaning a final conclusion could take considerable time.

Balance Sheet and Liquidity Risk

Capital impairment has continued for several years and total liabilities remain in the tens of billions of won on a consolidated basis, raising the possibility that further fundraising or debt restructuring may be needed.

Even after the change of largest shareholder to Iroom Holdings, whether the group continues to provide financial support remains an important variable.

Business Model Transition Risk

There is a possibility that the business focus could shift away from the traditional genomic analysis and diagnostics core toward health-supplement and precision-medicine platforms, and how the revenue contribution of existing flagship services would be reshaped in that process remains uncertain.

It is also worth noting that several new ventures have been attempted in the past without translating into meaningful revenue.

What to watch next

Around November 2026
The statutory filing deadline for the third-quarter 2026 report is expected around this time — a point to check the pace of revenue recovery, the trend in operating profit, and whether any further one-off items appear.
When the ruling on the underlying lawsuit over the delisting injunction is announced
The Seoul Southern District Court's ruling on the merits will determine whether the listing is maintained and whether the listing-eligibility substantive review resumes.
When the KOSDAQ Market Division implements follow-up market actions on the administrative-issue and investor-caution designations
The August 2026 half-year report disclosed that some designation grounds had been resolved, but market action remains on hold pending the litigation outcome, so it is worth confirming whether the action is actually implemented.
When a concrete business-collaboration agreement or new product launch with Iroom Holdings or Hugen Bio is announced
This will be the point to check whether the touted precision-medicine and health-supplement synergies actually translate into revenue.
When the FY2026 audit report is filed (typically around March of the following year)
Whether the audit opinion converts to an unqualified opinion is a key requirement for maintaining the listing and needs to be confirmed.

Overall view

EDGC is a company that restructured its capital base under a court-approved rehabilitation plan in March 2026, after going through an auditor's disclaimer of opinion and rehabilitation proceedings in 2024 and a delisting decision plus an injunction in November 2025.

In this process, healthcare group Iroom Holdings became the largest shareholder, and the company is seeking to reshape its business by combining its core genomic analysis and diagnostics operations with the group's health-supplement and hospital network.

On the financial statements, net income summed over the most recent four quarters showed a large profit, but this was mostly a one-off effect from debt restructuring and debt-to-equity conversion, and operating profit has still not escaped losses in any quarter.

Capital impairment also remains unresolved, and uncertainty over whether the listing will be maintained persists as the litigation over listing eligibility has not been finalized.

Investors should take into account the special circumstances of the rehabilitation and restructuring phase and distinguish between one-off items and core-business performance. This report does not include a buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.